Table 1. Parameters at the end of the experiment.
| Bwt (g) | PPBG (mg/dL) | Plasma Insulin (ng/mL) | TG (mg/dL) | TCho (mg/dL) | NEFA (mEq/L) | |
|---|---|---|---|---|---|---|
| C57BL6 | 28.83±0.38 | 130.70±4.79 | 0.22±0.02 | 44.33±4.17 | 76.00±10.58 | 0.90±0.01 |
| C57BL6+0.9% NaCl | 27.80±0.49 | 116.10±3.68 | 0.23±0.02 | 39.20±7.93 | 87.00±5.11 | 0.88±0.02 |
| KK-Ay | 45.58±1.14a | 498.30±40.17 a | 1.98±0.08 a | 430.80±46.36 a | 129.60±8.25 a | 1.14±0.20 |
| KK-Ay+0.9% NaCl | 44.63±1.16b | 422.10±25.86 b | 1.91±0.17 b | 438.40±50.11 b | 130.80±8.52 b | 1.17±0.27 |
| KK-Ay+0.9% NaCl +olmesartan | 46.87±0.97 | 378.50±40.12 | 1.30±0.14c,d | 326.50±55.34 c,d | 95.50±7.41 c,d | 0.92±0.10 |
| KK-Ay+0.9% NaCl +olmesartan+azelnidipine | 46.97±1.88 | 360.20±39.41 | 0.97±0.03e | 205.00±35.04e | 78.00±5.01e | 0.96±0.03 |
Bwt; body weight, PPBG; post prandial blood glucose, TG; triglyceride, TCho; total cholesterol, NEFA; Non-esterified fatty acid. a P < 0.05 vs. C57BL/6, b P < 0.05 vs. C57BL/6 + 0.9% NaCl, c P < 0.05 vs. KK-Ay, d P < 0.05 vs. KK-Ay + 0.9% NaCl, e P < 0.05 vs. KK-Ay + 0.9% NaCl + olmesartan.